299181-33-2

Basic information

• Product Name: 4-methoxy-3-(morpholine-4-sulfonyl)-benzoic acid
• Synonyms: 4-methoxy-3-(morpholine-4-sulfonyl)-benzoic acid
• CAS NO: 299181-33-2
• Molecular Weight: 301.32
• Mol File: 299181-33-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-methoxy-3-(morpholine-4-sulfonyl)-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-3-(morpholine-4-sulfonyl)-benzoic acid(299181-33-2)
• EPA Substance Registry System: 4-methoxy-3-(morpholine-4-sulfonyl)-benzoic acid(299181-33-2)

Safety Data

• Hazardous Substances Data: 299181-33-2(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 50803-29-7 3-chlorosulfonyl-4-methoxybenzoic acid 
• 100-09-4 4-methoxybenzoic acid 
• 353467-19-3 methyl 4-methoxy-3-(morpholinosulfonyl)benzoate 

Downstream Products

• 1025772-17-1 (R)-N-(1-(3-chlorophenyl)ethyl)-4-methoxy-3-(morpholinosulfonyl)benzamide 
• 299180-69-1 2,2'-Thiobis[5-[[4-methoxy-3-(4-morpholinylsulfonyl)benzoyl]amino]benzenesulfonic Acid] 
• 299180-68-0 4,4'-bis[4-methoxy-3-(morpholine-4-sulfonyl)benzoylamino]biphenyl-2,2'-(bis)sulfonic acid 

Relevant articles and documents

Synthesis and Biological Evaluation of 4-Sulfamoylphenyl/Sulfocoumarin Carboxamides as Selective Inhibitors of Carbonic Anhydrase Isoforms hCA II, IX, and XII

With the aim to develop potent and selective human carbonic anhydrase inhibitors (hCAIs), we synthesized 4-sulfamoylphenyl/sulfocoumarin benzamides (series 5 a–r and series 7 a–q) and evaluated their inhibition profiles against five isoforms of the zinc-containing human carbonic anhydrase (hCA, EC 4.2.1.1): cytosolic hCA I and II, and the transmembrane isozymes hCA IV, IX, and XII. Compounds 5 a–r were found to selectively inhibit hCA II in the nanomolar range, while being less effective against the other hCA isoforms. As noted from the literature, sulfocoumarin (1,2-benzoxathiine 2,2-dioxide) acts as a “prodrug” inhibitor and is hydrolyzed by the esterase activity of hCA to form 2-hydroxyphenylvinylsulfonic acid, which thereafter binds to the enzyme in a manner similar to that of coumarins and sulfoxocoumarins. All these sulfocoumarins (compounds 7 a–q) were found to be very weak or ineffective as inhibitors of the housekeeping off-target hCA isoforms I and II, and effectively inhibited the transmembrane tumor-associated isoforms IX and XII in the high nanomolar to micromolar ranges. Further structural modifications of these molecules could be useful for the development of effective hCA inhibitors used for the treatment of glaucoma, epilepsy, and cancer.

Aryl sulfonic acids and derivatives as FSH antagonists

This invention provides compounds of formula I having the structure wherein R1, Ar, Ar′, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof, which are useful as contraceptive agents.